Feasibility and Safety of Outpatient Hypomethylating Agent (HMA) + Venetoclax (Ven) Initiation +/- Ramp-up for Patients (pts) with Newly-Diagnosed Acute Myeloid Leukemia (AML)
Blood | November 29, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 8921-8922
10.1182/blood-2022-165446